Evolution of arterial redox potential during CPB. by Vincent Pey (21433304)

Subjects:

Theoretical frameworks of social protection. by Na Chen (153323)

Subjects:

Average per capita transfer amounts in different countries. by Na Chen (153323)

Subjects:

Cohort characteristics. by Vincent Pey (21433304)

Subjects:

Descriptive table of circulatory variables during CPB. by Vincent Pey (21433304)

Subjects:

Mean scores, standard deviations, and significance on key measures and subscales by gender group. by Silas Manning (22693338)

Subjects:

Time points and measurements. by Anne Wojtanowski (17507992)

Ecological and Health Risk Mediated by Micro(nano)plastics Aging Process: Perspectives and Challenges by Kexiao Song (13003200)

“…The changes in the physical and chemical characteristics of aged MNPs significantly influence their environmental behavior by releasing additives, forming byproducts, and adsorbing contaminants. …”

Ecological and Health Risk Mediated by Micro(nano)plastics Aging Process: Perspectives and Challenges by Kexiao Song (13003200)

“…The changes in the physical and chemical characteristics of aged MNPs significantly influence their environmental behavior by releasing additives, forming byproducts, and adsorbing contaminants. …”

Equilibrium points and their eigenvalues. by Chan He (5016737)

Potato gene ontology enrichment results significant at <i>p</i> < 0.01. by Margaret A. Carpenter (6104180)

Genome-wide significant SNPs for meat L*15 min and a*15 min. by Jiahong Sun (6497603)

Statistically Significant Results for Heart Rate Variability (HRV) Indices for High and Low Authority Groups. by David Vagni (8060432)

Subjects:

Statistically Significant Results for Heart Rate Variability (HRV) Indices for High and Low Clarity Groups. by David Vagni (8060432)

Subjects:

Identification of ACADM, ANGPTL4, and NFKB2 as significant predictors of OS in the TCGA-KIRC cohort. by Yu Zhang (12946)

Subjects:

Changes in AL (A) and SE (B) according to the treatment time estimation curve in patients given 0.125% atropine. by Zi-Rong Chen (9227618)

Subjects:

Flow diagram of the patient selection into the final analysis. by Zi-Rong Chen (9227618)

Subjects:

Patients’ demographics and clinical parameters. by Zi-Rong Chen (9227618)

Subjects:

Associations between demographic variables, In4_SED and SE changes at 6 and 12 months after 4_SED (<i><i>n</i></i> = 80). by Zi-Rong Chen (9227618)

Subjects:

Table 2 - Early identification of the efficacy of 0.125% atropine treatment for children with Myopia: A prospective pilot study by Zi-Rong Chen (9227618)

Subjects: